A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

Bowles DW, Senzer N, Hausman D, Peterson S, Vo A, Walker L, Cohen RB, Jimeno A. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2014 Dec; 32(6):1197-203.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell
Cetuximab
Class I Phosphatidylinositol 3-Kinases
Colorectal Neoplasms
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Gonanes
Head and Neck Neoplasms
Humans
Male
Maximum Tolerated Dose
Middle Aged
Mutation
Neoplasm Recurrence, Local
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras)
ras Proteins
Response Evaluation Criteria in Solid Tumors

authors with profiles

Daniel W Bowles